Wealthcare Advisory Partners LLC Sells 2,254 Shares of AbbVie Inc. $ABBV

Wealthcare Advisory Partners LLC lowered its position in AbbVie Inc. (NYSE:ABBV) by 4.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 50,422 shares of the company’s stock after selling 2,254 shares during the period. Wealthcare Advisory Partners LLC’s holdings in AbbVie were worth $12,688,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Paladin Wealth LLC purchased a new stake in AbbVie during the second quarter valued at about $212,000. Financial Management Professionals Inc. increased its stake in shares of AbbVie by 0.8% in the second quarter. Financial Management Professionals Inc. now owns 6,071 shares of the company’s stock worth $1,528,000 after purchasing an additional 50 shares in the last quarter. First Bank & Trust raised its position in shares of AbbVie by 3.1% in the second quarter. First Bank & Trust now owns 20,753 shares of the company’s stock valued at $5,222,000 after purchasing an additional 626 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of AbbVie by 2.3% during the 2nd quarter. Revolve Wealth Partners LLC now owns 7,998 shares of the company’s stock valued at $2,013,000 after buying an additional 177 shares in the last quarter. Finally, Ares Financial Consulting LLC lifted its stake in shares of AbbVie by 6.3% during the 2nd quarter. Ares Financial Consulting LLC now owns 980 shares of the company’s stock valued at $247,000 after buying an additional 58 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Apogee acquisition strengthens immunology pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, or $135.11 per share in cash. The deal adds zumilokibart, an investigational therapy for atopic dermatitis, asthma and other inflammatory diseases. Positive Phase 2 data support planned Phase 3 development, potentially helping AbbVie diversify its immunology portfolio and extend growth beyond existing products. The transaction is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
• Positive Sentiment: Botox Cosmetic could gain a fifth indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence, a jaw-muscle condition associated with a wider facial appearance. FDA acceptance does not guarantee approval, but a new aesthetic use could expand Botox’s addressable market and support growth in one of AbbVie’s best-known brands. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
• Positive Sentiment: Analyst sentiment remains constructive: Brokerages maintain a consensus “Moderate Buy” rating, and commentary following second-quarter results characterized ABBV as a potentially undervalued dividend and growth opportunity. AbbVie Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Strong operating performance is balanced by valuation: AbbVie’s latest quarter exceeded EPS and revenue expectations, with revenue rising 10.2% year over year, driven by SKYRIZI, RINVOQ and neuroscience products. However, the stock’s elevated P/E ratio leaves less room for execution or regulatory disappointments. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
• Negative Sentiment: Execution and deal risks remain: The Apogee transaction requires approvals and could bring integration costs and development risk if zumilokibart fails to reproduce its Phase 2 results in larger trials. AbbVie must also manage ongoing biosimilar pressure and sustain growth from its core immunology products.

AbbVie Trading Up 0.7%

ABBV stock opened at $247.86 on Tuesday. The company’s 50 day moving average is $242.67 and its 200 day moving average is $225.28. The stock has a market cap of $437.92 billion, a price-to-earnings ratio of 70.02, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the business posted $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is currently 195.48%.

Analysts Set New Price Targets

A number of research firms recently weighed in on ABBV. HSBC reiterated a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Guggenheim lifted their price target on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Bank of America boosted their price objective on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Finally, Barclays lifted their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $275.70.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.